Bulletin
Investor Alert

London Markets Close in:

Capitol Report Archives | Email alerts

Dec. 7, 2020, 6:13 p.m. EST

White House denies report saying it passed when Pfizer offered additional vaccine doses

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Pfizer Inc. (PFE)
  • X
    Moderna Inc. (MRNA)
  • X
    CVS Health Corp. (CVS)

or Cancel Already have a watchlist? Log In

By Victor Reklaitis

Trump administration officials on Monday denied a New York Times report that said they passed when Pfizer offered in late summer to sell the U.S. government additional doses of its COVID-19 vaccine candidate.

Now Pfizer /zigman2/quotes/202877789/composite PFE -0.71% may not be able provide more of its vaccine to the U.S. until next June because of its commitments to other nations, the report added.

Senior administration officials told reporters on a conference call that the Times report was false, and the administration expects to have enough doses to vaccinate all Americans who want one before the end of next year’s second quarter.

Administration officials also played down news that Moderna /zigman2/quotes/205619834/composite MRNA -1.84% and Pfizer, developers of COVID-19 vaccine candidates, will not participate in a vaccine summit planned for Tuesday.

Pfizer and Moderna rejected invitations to the summit from President Donald Trump, according to a STAT News report on Monday. The report added that drug-industry figures viewed the event as a public-relations stunt.

But the administration officials countered that it was “more appropriate” not to have vaccine companies with pending applications before the Food and Drug Administration participate in the summit, given that an FDA official was taking part.

The administration officials said Tuesday’s summit would involve representatives from CVS /zigman2/quotes/209664499/composite CVS -0.30% , Walgreens /zigman2/quotes/203410933/composite WBA -0.12% , UPS /zigman2/quotes/201245396/composite UPS +0.72% , FedEx /zigman2/quotes/203047719/composite FDX +0.71% , McKesson /zigman2/quotes/206975466/composite MCK +0.29% and Thermo Fisher /zigman2/quotes/201150432/composite TMO +1.04% .

/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 42.76
-0.30 -0.71%
Volume: 13.50M
July 29, 2021 11:28a
P/E Ratio
21.73
Dividend Yield
3.65%
Market Cap
$243.22 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 342.88
-6.44 -1.84%
Volume: 5.96M
July 29, 2021 11:28a
P/E Ratio
275.16
Dividend Yield
N/A
Market Cap
$140.26 billion
Rev. per Employee
$617,996
loading...
/zigman2/quotes/209664499/composite
US : U.S.: NYSE
$ 83.05
-0.25 -0.30%
Volume: 1.36M
July 29, 2021 11:28a
P/E Ratio
14.80
Dividend Yield
2.41%
Market Cap
$109.67 billion
Rev. per Employee
$895,513
loading...
/zigman2/quotes/203410933/composite
US : U.S.: Nasdaq
$ 47.06
-0.05 -0.12%
Volume: 901,445
July 29, 2021 11:28a
P/E Ratio
17.86
Dividend Yield
4.05%
Market Cap
$40.75 billion
Rev. per Employee
$421,562
loading...
/zigman2/quotes/201245396/composite
US : U.S.: NYSE
$ 193.42
+1.38 +0.72%
Volume: 982,627
July 29, 2021 11:28a
P/E Ratio
27.46
Dividend Yield
2.12%
Market Cap
$167.18 billion
Rev. per Employee
$155,492
loading...
/zigman2/quotes/203047719/composite
US : U.S.: NYSE
$ 283.84
+2.01 +0.71%
Volume: 723,029
July 29, 2021 11:27a
P/E Ratio
18.69
Dividend Yield
1.06%
Market Cap
$75.35 billion
Rev. per Employee
$289,945
loading...
/zigman2/quotes/206975466/composite
US : U.S.: NYSE
$ 204.76
+0.60 +0.29%
Volume: 130,028
July 29, 2021 11:25a
P/E Ratio
N/A
Dividend Yield
0.92%
Market Cap
$31.58 billion
Rev. per Employee
$3.13M
loading...
/zigman2/quotes/201150432/composite
US : U.S.: NYSE
$ 533.74
+5.47 +1.04%
Volume: 344,564
July 29, 2021 11:27a
P/E Ratio
26.84
Dividend Yield
0.19%
Market Cap
$207.62 billion
Rev. per Employee
$402,725
loading...

This Story has 0 Comments
Be the first to comment
More News In
Economy & Politics

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.